CLRB - セレクタ・バイオサイエンシ―ズ （Cellectar Biosciences Inc.） セレクタ・バイオサイエンシ―ズCLRBのチャート
CLRBの企業情報
| symbol | CLRB |
|---|---|
| 会社名 | Cellectar Biosciences Inc （セレクタ・バイオサイエンシ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Cellectar Biosciences Inc. formerly Novelos Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic PDC''s. The Company''s PDC product portfolio includes CLR 131 which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125 which is for the treatment of micro metastatic disease; CLR 124 which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502 which is for intraoperative tumor margin illumination and non-invasive tumor imaging and CTX Product Portfolio including CLR 1601-PTX CLR 1602-PTX and CLR 1603-PTX product candidates. セレクタ・バイオサイエンシ―ズは米国のバイオ医薬品企業。癌治療薬、癌標的の投影剤の開発に従事。同社の癌注力技術は癌幹細胞を含む癌細胞に対する薬剤の選択的送達を可能にする。開発中の製品候補は、癌標的陽電子放射断層撮影造影剤I-124-CLR1404、癌標的分子放射線治療I-131-CLR1404、非放射光造影剤CLR1502など。 Cellectar Biosciences Inc is a biopharmaceutical company. It is engaged in developing compounds for treatment and imaging of cancer. Its portfolio consists of PET imaging agents, optical imaging agents, and therapeutic agents. |
| 本社所在地 | 3301 Agriculture Drive Madison WI 53716 USA |
| 代表者氏名 | Stephen Anthony Hill スティーブン・アンソニー・ヒル |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 608-441-8120 |
| 設立年月日 | 35217 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.cellectar.com |
| nasdaq_url | https://www.nasdaq.com/symbol/clrb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.53883 |
| 終値（lastsale） | 2.715 |
| 時価総額（marketcap） | 10311094.875 |
| 時価総額 | 時価総額（百万ドル） 10.21615 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6.03918 |
| 当期純利益 | 当期純利益（百万ドル） -15.39489 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cellectar Biosciences Inc revenues was not reported. Net loss increased 6% to $6.4M. Higher net loss reflects (Loss)/Gain on revaluation of derivative decrease from $8K (income) to $47K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.73 to -$3.75. |
CLRBのテクニカル分析
CLRBのニュース
FCEL, STM among premarket gainers 2019-05-21
CIRCOR (NYSE: CIR ) +51% on Crane buyout offer . More news on: CIRCOR International, Inc., JMU Limited, Biocept, Inc., Stocks on the move, Read more …
Midday movers and shakers 2019-01-18
Gainers: Sonic Foundry ( OTC:SOFO ) +19% . Rafael Holdings (NYSEMKT: RFL ) +15% . Turtle Beach (NASDAQ: HEAR ) +14% . Hi-Crush Partners LP (NYSE: HCLP ) +14% . Bank OZK (NASDAQ: OZK ) +14% . Superior Drilling Products (NYSEMKT: SDPI ) +13% . Cellectar Biosciences (NASDAQ: CLRB ) +1…